Panoramic: Automotive and Mobility 2025
Pharmaceuticals and Biotechnology
Drug companies face pressure from many directions – from a foreboding regulatory landscape, from competitors with alternative brands or generics, from insurers pushing back on prescription drug costs and reimbursement.
Whether you're a global pharmaceuticals company or a biotechnology startup, accomplishing business goals in such a highly regulated industry requires practical, integrated legal analysis and advice. At the same time, you can find opportunities in maximizing the benefits of statutes that encourage new drug development.
Our capabilities at a glance
00
+
Judicial review wins
2
Ex-government policy advisors
00
+
Pieces of legislation changed
Hear from our clients and industry leaders
The whole team is super smart. They are all really easy to work with and then know our business inside out. They come to us proactively with issues and are incredibly responsive.
Chambers & Partners, UK Guide, 2025
An intellectually brilliant and commercially astute public law team. One of the very best in the city.
Chambers & Partners UK 2025
Hogan Lovells has a high capability in solving complex issues that involve both legal and technical perspectives.
Chambers & Partners, Germany, 2025
The lawyers are just experts. They are there when you need them and happy to entertain all my questions. They understand the wider context and the politics and sensitivities of it.
Chambers & Partners, UK 2025
Key contacts
Representative experience
Novartis on the Series C investment in Pliant Therapeutics Inc., a company focused on discovering and developing novel therapies to slow or halt the progression of multiple fibrotic diseases.
Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.
Medigene AG in US$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.
Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.
Novartis on its US$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.
A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.
DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.
Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck’s antibiotic drug, Invanz®.
Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.
A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.
A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.
Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.
Awards and recognitions
Band 1 for Life Sciences
Chambers Global: Multi-Jurisdictional
2025
Band 1 for Life Sciences
Chambers Europe-wide
2025
Band 1 for Life Sciences in Japan
Chambers Asia-Pacific
2025
Navigate change with our latest insights
